Announcement

On October 8, 2026, Löviselle issued a press release announcing the launch of its first Malaysian LEAP (Learning, Education, and Practice) program at the Medical Academy of Malaysia, building on the inaugural edition held at a leading Singapore Medical Academy.

Program Details

The two‑day Malaysian event gathered more than 60 local physicians under the theme “Beyond Stimulation, True Regeneration.” The agenda spanned from scientific rationale to hands‑on clinical practice, aiming to create a connected regional academic platform across Singapore and Malaysia.

Scientific Content

Dr. Ding Huilin of Shanghai Jiahui International Hospital delivered the foundational science segment, introducing LaSynPro® Bio‑Active Regeneration technology. He explained that, unlike conventional biostimulators that rely on a passive foreign‑body reaction to induce collagen, LaSynPro® activates the tissue’s intrinsic repair mechanisms, delivering more natural, controllable, and durable outcomes.

Clinical Insights

Dr. Yang Xi, Technical Director of Shanghai Zhimei Medical Clinic, translated the science into practice during the Singapore LEAP and reiterated the concepts in Malaysia. She showcased Löviselle’s treatment protocol design and injection techniques, stressing that successful results depend on precise matching of tissue layers, product characteristics, and aesthetic goals rather than merely stacking materials.

Technology Advantage

Across both programs, physicians highlighted the generational advantage of Löviselle’s Next Generation PLLA technology over conventional PLLA products. The key differentiation lies in promoting tissue self‑remodeling rather than simple stimulation, aligning with a patient trend toward “natural” anti‑aging solutions that enhance appearance subtly.

Future Plans

Löviselle announced that the LEAP series will continue expanding throughout Southeast Asia, with upcoming advanced training, case workshops, and international faculty exchanges planned for Malaysia and other regional markets. The company emphasizes its commitment to building a lasting clinical community rooted in bio‑active regeneration.

Disclaimer

The release notes that it is distributed under an arrangement with PRNewswire and that PTI assumes no editorial responsibility for the content.